Market
Percentage of Zepbound users symptom-free after one year by 2025?
2
Resolution / Starting Odds
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
Clinical trial results and patient outcome studies
Story
FDA Approves Eli Lilly's Weight-Loss Drug Zepbound as First Treatment for Obstructive Sleep Apnea
Dec 20, 2024, 10:17 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's weight-loss drug Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This approval allows the drug to be used in combination with a reduced-calorie diet and increased physical activity. Clinical studies have shown that patients treated with Zepbound experienced a mean reduction of 63% in the apnea-hypopnea index (AHI), equating to about 30 fewer breathing interruptions per hour, and up to 50% of patients had no symptoms after one year. The approval opens the door for broader insurance coverage of the medication, marking a significant advancement in the management of obstructive sleep apnea, a condition affecting approximately 39 million adults in the United States.
View original story
Similar markets
40% to 50% • 25%
More than 60% • 25%
51% to 60% • 25%
Less than 40% • 25%
26-50% reduction • 25%
76-100% reduction • 25%
0-25% reduction • 25%
51-75% reduction • 25%
70% to 80% • 25%
60% to 70% • 25%
Less than 60% • 25%
More than 80% • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
No • 50%
Yes • 50%
11 to 15 • 25%
More than 15 • 25%
Less than 5 • 25%
5 to 10 • 25%
100,000 to 200,000 • 25%
Less than 100,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
20% to 30% • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%